Infliximab is:
Infliximab: It is a chimeric monoclonal antibody which binds and neutralizes TNF-alpha dose- 3-5 mg/kg is infused i.v. every weeks. An acute reaction comprising of fever, chills, Uicaria, bronchospasm, rarely anaphylaxis may follow infusion. Susceptibility to respiratory infections is Increased and worsening of CHF has been noted. It is initially combined with Mtx which improves the response decreases antibody formation against infliximab. REF KD TRIpathi 8th ed